Joseph P Nkolola

List of Publications by Year
in descending order

46 papers	7,174 citations	159585 30 h-index	206112 48 g-index
49 all docs	49 docs citations	49 times ranked	12213 citing authors

#	Article	IF	Citations
1	Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. Nature, 2022, 601, 612-616.	27.8	14
2	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. Med, 2022, 3, 188-203.e4.	4.4	11
3	HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. PLoS Pathogens, 2022, 18, e1010467.	4.7	15
4	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nature Medicine, 2022, 28, 1288-1296.	30.7	44
5	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	6.0	4
6	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. Science Translational Medicine, 2022, 14, .	12.4	3
7	Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques. Journal of Virology, 2021, 95, .	3.4	87
8	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. Nature Communications, 2021, 12, 1474.	12.8	26
9	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	7.4	260
10	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. Journal of Virology, 2021, 95, .	3.4	80
11	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature, 2021, 596, 423-427.	27.8	40
12	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature, 2021, 596, 268-272.	27.8	290
13	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA - Journal of the American Medical Association, 2021, 325, 2370.	7.4	307
14	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. Frontiers in Immunology, 2021, 12, 709994.	4.8	4
15	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature Medicine, 2021, 27, 1718-1724.	30.7	39
16	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell, 2020, 183, 185-196.e14.	28.9	25
17	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586, 583-588.	27.8	765
18	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. Nature Biomedical Engineering, 2020, 4, 1030-1043.	22.5	46

#	Article	IF	Citations
19	Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature, 2020, 584, 443-449.	27.8	956
20	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 1061-1070.	9.1	36
21	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020, 369, 812-817.	12.6	789
22	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020, 369, 806-811.	12.6	978
23	Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zikaâ€specific antibodies. American Journal of Reproductive Immunology, 2020, 84, e13288.	1.2	7
24	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nature Medicine, 2020, 26, 498-501.	30.7	43
25	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq1 1 0.784314 rgBT /O	4.0	49
26	Lack of therapeutic efficacy of an antibody to Î± ₄ Î² ₇ in SIVmac251-infected rhesus macaques. Science, 2019, 365, 1029-1033.	12.6	31
27	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity, 2019, 50, 241-252.e6.	14.3	153
28	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	11.0	124
29	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of Infectious Diseases, 2018, 218, 633-644.	4.0	35
30	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. Journal of Virology, 2018, 92, .	3.4	10
31	First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS ONE, 2018, 13, e0205139.	2.5	32
32	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature, 2018, 563, 360-364.	27.8	246
33	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, The, 2018, 392, 232-243.	13.7	269
34	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nature Medicine, 2018, 24, 721-723.	30.7	46
35	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity, 2017, 46, 1073-1088.e6.	14.3	286
36	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nature Communications, 2017, 8, 15740.	12.8	11

#	Article	IF	Citations
37	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	12.4	106
38	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Journal of Virology, 2017, 91, .	3.4	38
39	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature, 2016, 540, 284-287.	27.8	246
40	SIV Infection-Mediated Changes in Gastrointestinal Bacterial Microbiome and Virome Are Associated with Immunodeficiency and Prevented by Vaccination. Cell Host and Microbe, 2016, 19, 323-335.	11.0	78
41	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science, 2015, 349, 320-324.	12.6	303
42	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. Journal of Virology, 2015, 89, 2507-2519.	3.4	42
43	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. Journal of Virology, 2014, 88, 9538-9552.	3.4	30
44	Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine, 2014, 32, 2109-2116.	3.8	27
45	Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies. PLoS ONE, 2014, 9, e97229.	2.5	59
46	Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs. Journal of Virology, 2010, 84, 3270-3279.	3.4	89